Design, synthesis and evaluation of novel bifunctional tetrahydroxamate chelators for PET imaging of 89Zr-labeled antibodies

被引:20
|
作者
Rousseau, Julie [1 ]
Zhang, Zhengxing [1 ]
Dias, Gemma M. [1 ]
Zhang, Chengcheng [1 ]
Colpo, Nadine [1 ]
Benard, Francois [1 ,2 ,3 ]
Lin, Kuo-Shyan [1 ,2 ,3 ]
机构
[1] BC Canc Agcy, Dept Mol Oncol, Vancouver, BC V5Z 1L3, Canada
[2] BC Canc Agcy, Dept Funct Imaging, Vancouver, BC V5Z 4E6, Canada
[3] Univ British Columbia, Dept Radiol, Vancouver, BC V5Z 4E3, Canada
关键词
Zirconium-89; Bifunctional chelators; Antibody; Trastuzumab; Molecular imaging; Positron emission tomography; ZR-89; ZIRCONIUM-89; LIGANDS;
D O I
10.1016/j.bmcl.2017.01.052
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Two compact and symmetrical bifunctional tetrahydroxamate chelators, 1 and 2, were synthesized and evaluated for labeling antibodies with Zr-89 for imaging with positron emission tomography. Using 2,2'-iminodiacetamide as the backbone, four hydroxamate-containing moieties coupled to the diacetamide nitrogen were used for Zr-89 labeling, while a pendant connected to the amino group provided an isothiocyanate group for coupling to the antibody. Both 1- and 2-conjugated Trastuzumab were labeled with Zr-89 efficiently (>90% radiolabeling yield), and their Zr-89-labeled products maintained comparable immunoreactivity to Trastuzumab. Compared to Zr-89-labeled deferoxamine-conjugated Trastuzumab, Zr-89-1- and Zr-89-2-Trastuzumab showed faster demetalation in mouse plasma, and also displayed higher bone uptake in mice. Despite suboptimal stability of Zr-89 complexes of 1 and 2, our design strategy led to tetrahydroxamate chelators for efficient Zr-89 labeling, and could be potentially modified to provide novel chelators with improved stability. (C) 2017 Elsevier Ltd. All rights reserved.
引用
收藏
页码:708 / 712
页数:5
相关论文
共 50 条
  • [41] Inter-observer agreement for tumor uptake quantification of 89Zr-labeled anti-CD20 antibodies with PET
    Jauw, Yvonne
    Hoekstra, Otto
    Mulder, Emma
    Pieplenbosch, Simone
    Hoetjes, Nikie
    Van Dongen, Guus
    Zweegman, Sonja
    Zijlstra, Josee
    Huisman, Marc
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [42] Detection limit of 89Zr-labeled T cells for cellular tracking: an in vitro imaging approach using clinical PET/CT and PET/MRI
    Lechermann, Laura M.
    Manavaki, Roido
    Attili, Bala
    Lau, Doreen
    Jarvis, Lorna B.
    Fryer, Tim D.
    Bird, Nick
    Aloj, Luigi
    Patel, Neel
    Basu, Bristi
    Cleveland, Matthew
    Aigbirhio, Franklin, I
    Jones, Joanne L.
    Gallagher, Ferdia A.
    EJNMMI RESEARCH, 2020, 10 (01)
  • [43] Disparity Between In Vivo EGFR Expression and 89Zr-Labeled Cetuximab Uptake Assessed with PET
    Aerts, Hugo J. W. L.
    Dubois, Ludwig
    Perk, Lars
    Vermaelen, Peter
    van Dongen, Guus A. M. S.
    Wouters, Bradly G.
    Lambin, Philippe
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50 (01) : 123 - 131
  • [44] 89Zr-Labeled renal clearable polyoxometalate cluster for positron emission tomography imaging
    Nil, Dalong
    Jiang, Dawei
    Im, Hyung-Jun
    Valdovinosi, Hector
    Yur, Bo
    Barnhart, Todd
    Cai, Weibo
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58
  • [45] ImmunoPET Imaging of Pancreatic Tumors with 89Zr-Labeled Gold Nanoparticle–Antibody Conjugates
    Nicholas B. Sobol
    Joshua A. Korsen
    Ali Younes
    Kimberly J. Edwards
    Jason S. Lewis
    Molecular Imaging and Biology, 2021, 23 : 84 - 94
  • [46] Imaging and quantification of 89Zr-labeled antibodies in rhesus monkeys up to 30 days post-injection using the mini-EXPLORER PET scanner
    Berg, Eric
    Zhang, Xuezhu
    Gill, Herman
    Marik, Jan
    Tarantal, Alice
    Williams, Simon
    Cherry, Simon
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [47] PET with the 89Zr-Labeled Transforming Growth Factor-β Antibody Fresolimumab in Tumor Models
    Munnink, Thijs H. Oude
    Arjaans, Marlous E. A.
    Timmer-Bosscha, Hetty
    Schroder, Carolina P.
    Hesselink, Jan W.
    Vedelaar, Silke R.
    Walenkamp, Annemiek M. E.
    Reiss, Michael
    Gregory, Richard C.
    Lub-de Hooge, Marjolijn N.
    de Vries, Elisabeth G. E.
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52 (12) : 2001 - 2008
  • [48] In vitro and in vivo evaluation of a 89Zr-labeled anti-TIP1 antibody
    Boas, Cristian Wieczorek Villas
    Lewis, Calvin
    Signh, Abhay
    Hallahan, Dennis
    Kapoor, Vaishali
    Rogers, Buck
    NUCLEAR MEDICINE AND BIOLOGY, 2022, 108 : S37 - S38
  • [49] Detection limit of 89Zr-labeled T cells for cellular tracking: an in vitro imaging approach using clinical PET/CT and PET/MRI
    Laura M. Lechermann
    Roido Manavaki
    Bala Attili
    Doreen Lau
    Lorna B. Jarvis
    Tim D. Fryer
    Nick Bird
    Luigi Aloj
    Neel Patel
    Bristi Basu
    Matthew Cleveland
    Franklin I. Aigbirhio
    Joanne L. Jones
    Ferdia A. Gallagher
    EJNMMI Research, 10
  • [50] 89Zr-Labeled High-Density Lipoprotein Nanoparticle PET Imaging Reveals Tumor Uptake in Patients with Esophageal Cancer
    Zheng, Kang H.
    Kroon, Jeffrey
    Schoormans, Jasper
    Gurney-Champion, Oliver
    Meijer, Sybren L.
    Gisbertz, Suzanne S.
    Hulshof, Maarten C. C. M.
    Vugts, Danielle J.
    van Dongen, Guus A. M. S.
    Coolen, Bram F.
    Verberne, Hein J.
    Nederveen, Aart J.
    Stroes, Erik S. G.
    van Laarhoven, Hanneke W. M.
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (12) : 1880 - 1886